AVBP Stock Analysis: Buy, Sell, or Hold?
AVBP - ArriVent BioPharma, Inc. Common Stock
$33.74
1.04 (3.18%)
▲
5d:
+11.35%
30d:
+24.96%
90d:
+52.12%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.0/10
Get Alerted When AVBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AVBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AVBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AVBP is currently trading at $33.74, which is considered extended relative to its 30-day fair value range of $27.59 to $31.71.
Technical Outlook: Technically, AVBP is in a strong uptrend. The price is approaching resistance at $34.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: AVBP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.64 (+33.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AVBP is in a strong uptrend. The price is approaching resistance at $34.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: AVBP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.64 (+33.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.59 -
$31.71
Company Quality Score
58/100
(HOLD)
Options IV Signal
48th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BEARISH: Price extended above range (+6.4% above its trading range)
- NEUTRAL: Options fairly priced (IV 48th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 33.4% below Wall St target ($43.64)
Trading Range Analysis
30-Day Trading Range
$27.59 -
$31.71
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$6.97
(20.7%)
Support & Resistance Levels
Support Level
$29.13
Resistance Level
$34.65
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.33
Wall Street Target
$43.64
(+33.4%)
Share & Embed Analysis
Last updated: June 23, 2026 3:51 PM ET
Data refreshes hourly during market hours. Next update: 4:51 PM
Data refreshes hourly during market hours. Next update: 4:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
